company background image
455

Tianda Pharmaceuticals SEHK:455 Stock Report

Last Price

HK$0.20

Market Cap

HK$438.6m

7D

9.1%

1Y

-10.5%

Updated

24 Jun, 2022

Data

Company Financials
455 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

455 Stock Overview

Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.

Tianda Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Tianda Pharmaceuticals
Historical stock prices
Current Share PriceHK$0.20
52 Week HighHK$0.36
52 Week LowHK$0.16
Beta0.60
1 Month Change4.61%
3 Month Change-8.93%
1 Year Change-10.53%
3 Year Change-9.74%
5 Year Change-41.71%
Change since IPO-65.13%

Recent News & Updates

Jan 11
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Aug 05
Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

455HK PharmaceuticalsHK Market
7D9.1%6.8%1.2%
1Y-10.5%-44.5%-23.3%

Return vs Industry: 455 exceeded the Hong Kong Pharmaceuticals industry which returned -44.5% over the past year.

Return vs Market: 455 exceeded the Hong Kong Market which returned -23.3% over the past year.

Price Volatility

Is 455's price volatile compared to industry and market?
455 volatility
455 Average Weekly Movement5.2%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement7.0%
10% most volatile stocks in HK Market13.7%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 455 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 455's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992714Alan Fanghttps://www.tiandapharma.com

Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range includes Chinese medicines, chemical drugs, biological and health products, and medical appliances covering the area of cardio-cerebrovascular, pediatric, flu and respiratory, anti-infection, detoxification, anti-cancer, and others. The company offers its health products under the Herb Valley and Tuokang brands.

Tianda Pharmaceuticals Fundamentals Summary

How do Tianda Pharmaceuticals's earnings and revenue compare to its market cap?
455 fundamental statistics
Market CapHK$438.61m
Earnings (TTM)-HK$29.54m
Revenue (TTM)HK$523.49m

0.8x

P/S Ratio

-14.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
455 income statement (TTM)
RevenueHK$523.49m
Cost of RevenueHK$277.90m
Gross ProfitHK$245.59m
Other ExpensesHK$275.13m
Earnings-HK$29.54m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Jun 29, 2022

Earnings per share (EPS)-0.014
Gross Margin46.91%
Net Profit Margin-5.64%
Debt/Equity Ratio19.3%

How did 455 perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

-19%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 455 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 455?

Other financial metrics that can be useful for relative valuation.

455 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA-22.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 455's PS Ratio compare to its peers?

455 PS Ratio vs Peers
The above table shows the PS ratio for 455 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.5x

Price-To-Sales vs Peers: 455 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does 455's PE Ratio compare vs other companies in the Hong Kong Pharmaceuticals Industry?

Price-To-Sales vs Industry: 455 is good value based on its Price-To-Sales Ratio (0.8x) compared to the Hong Kong Pharmaceuticals industry average (1.6x)


Price to Sales Ratio vs Fair Ratio

What is 455's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

455 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 455's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 455 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 455 (HK$0.2) is trading above our estimate of fair value (HK$0.05)

Significantly Below Fair Value: 455 is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 455's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Tianda Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianda Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Tianda Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Tianda Pharmaceuticals competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Tianda Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-73.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 455 is currently unprofitable.

Growing Profit Margin: 455 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 455 is unprofitable, and losses have increased over the past 5 years at a rate of 73.1% per year.

Accelerating Growth: Unable to compare 455's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 455 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).


Return on Equity

High ROE: 455 has a negative Return on Equity (-3.65%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Tianda Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 455's short term assets (HK$577.4M) exceed its short term liabilities (HK$202.6M).

Long Term Liabilities: 455's short term assets (HK$577.4M) exceed its long term liabilities (HK$145.7M).


Debt to Equity History and Analysis

Debt Level: 455 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 455's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 455 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 455 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 55.5% each year.


Discover healthy companies

Dividend

What is Tianda Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.27%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 455's dividend (1.27%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.76%).

High Dividend: 455's dividend (1.27%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.89%).


Stability and Growth of Payments

Stable Dividend: 455 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.

Growing Dividend: 455 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: 455 is not paying a notable dividend for the Hong Kong market.


Cash Payout to Shareholders

Cash Flow Coverage: 455 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

13.3yrs

Average board tenure


CEO

Alan Fang (52 yo)

5.33yrs

Tenure

HK$60,000

Compensation

Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...


Board Members

Experienced Board: 455's board of directors are seasoned and experienced ( 13.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tianda Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Tianda Pharmaceuticals Limited
  • Ticker: 455
  • Exchange: SEHK
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$438.609m
  • Shares outstanding: 2.15b
  • Website: https://www.tiandapharma.com

Number of Employees


Location

  • Tianda Pharmaceuticals Limited
  • CITIC Tower
  • 24th Floor
  • Central
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.